ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors

Business Wire India
ITM gains exclusive global development and commercialization rights to Debiopharm’s first-in-class, peptide-based theranostic …

Source: Businesswire – http://businesswireindia.com